Hospital
Dignity Health
Dignity Health was paid $18.73M by Medicaid between Jan 2018 and Dec 2024, across 266 billing codes. Its largest line is 99284, emergency room visit (serious) — 17% of everything it billed.
33Billing provider infoDIGNITY HEALTH
HENDERSON, NV 89052
HENDERSON, NV 89052
33aNPI1770626426assigned 02/14/2007
33bProvider typeGeneral Acute Care Hospital
28Total paid$18.73M
24GClaims1,200,571
24DCodes billed266
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Nevada
Rank by total paid#13 of 36
Median peer was paid$7.64M
This provider vs. median2.5×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official MORISSETTE, DANIEL controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 99,318 | $1.10M | |
| 2019 | 198,613 | $3.03M | |
| 2020 | 186,048 | $2.70M | |
| 2021 | 201,404 | $2.85M | |
| 2022 | 198,155 | $3.18M | |
| 2023 | 185,595 | $3.23M | |
| 2024incomplete | 131,438 | $2.63M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 17% | 43,667 | 35,010 | $3.12M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 14% | 28,406 | 21,615 | $2.67M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 10% | 39,822 | 34,791 | $1.93M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 8.5% | 8,407 | 6,437 | $1.60M |
| 70450 | Computed tomography, head or brain; without contrast material | 4.0% | 12,214 | 9,204 | $755K |
| G0378 | Hospital observation service, per hour | 3.7% | 12,666 | 6,584 | $685K |
| 71275 | Computed tomographic angiography, chest, with contrast material | 2.8% | 2,725 | 1,968 | $528K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 2.8% | 4,450 | 3,332 | $526K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 1.7% | 22,922 | 17,332 | $313K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 1.6% | 12,591 | 10,046 | $308K |
| 72125 | Computed tomography, cervical spine; without contrast material | 1.5% | 4,257 | 3,223 | $279K |
| 80053 | Comprehensive metabolic panel | 1.3% | 63,212 | 44,304 | $252K |
254 more codes
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 1.3% | 7,282 | $244K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | 1.1% | 2,242 | $203K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 1.1% | 15,874 | $198K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.0% | 71,867 | $190K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 3,628 | $173K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 4,698 | $168K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 16,137 | $158K |
| 99070 | <1% | 10,564 | $149K | |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 1,134 | $145K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 36,461 | $140K |
| 59025 | Fetal non-stress test | <1% | 5,215 | $136K |
| 71045 | Radiologic examination, chest; single view | <1% | 25,370 | $128K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 15,116 | $127K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 2,218 | $126K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 9,483 | $118K |
| 83880 | <1% | 11,992 | $116K | |
| 76801 | <1% | 2,151 | $114K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 7,030 | $107K |
| 0450 | Emergency room services | <1% | 2,526 | $107K |
| 72131 | <1% | 1,292 | $96K | |
| 84484 | <1% | 25,582 | $96K | |
| 54161 | <1% | 250 | $94K | |
| 76830 | Ultrasound, transvaginal | <1% | 1,386 | $91K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 8,649 | $82K |
| J3490 | Unclassified drugs | <1% | 33,156 | $78K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 6,378 | $77K |
| 96376 | <1% | 5,959 | $73K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 77,401 | $71K |
| 70496 | <1% | 290 | $70K | |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 3,855 | $70K |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 1,475 | $67K |
| 70486 | <1% | 598 | $67K | |
| 84703 | <1% | 21,559 | $65K | |
| 93971 | <1% | 1,606 | $64K | |
| J2785 | Injection, regadenoson, 0.1 mg | <1% | 859 | $60K |
| 87040 | <1% | 8,121 | $58K | |
| 83690 | <1% | 21,623 | $54K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 31,080 | $53K |
| 72128 | <1% | 469 | $52K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 619 | $51K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 6,869 | $47K |
| 70498 | <1% | 317 | $45K | |
| 93970 | <1% | 639 | $43K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 959 | $37K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 16,454 | $35K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 2,158 | $34K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 1,358 | $33K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 2,008 | $32K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 2,009 | $32K |
| 97161 | <1% | 3,296 | $32K | |
| 90715 | <1% | 1,551 | $30K | |
| 83605 | <1% | 8,335 | $29K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 9,482 | $29K |
| 81001 | <1% | 23,573 | $27K | |
| 85730 | <1% | 17,730 | $26K | |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 237 | $25K |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 15,077 | $25K |
| 85610 | <1% | 24,517 | $24K | |
| 83735 | <1% | 12,291 | $23K | |
| 85379 | <1% | 5,933 | $23K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 1,222 | $22K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 1,200 | $22K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 4,983 | $21K |
| 84702 | <1% | 3,512 | $21K | |
| 73630 | <1% | 1,276 | $20K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 1,848 | $20K |
| 87088 | <1% | 6,864 | $20K | |
| 73030 | <1% | 1,645 | $19K | |
| 97165 | <1% | 2,465 | $19K | |
| 74018 | <1% | 1,797 | $18K | |
| 73610 | <1% | 971 | $17K | |
| 73130 | <1% | 978 | $16K | |
| 78492 | <1% | 97 | $16K | |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | <1% | 836 | $15K |
| 82550 | <1% | 8,100 | $15K | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 7,972 | $15K |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 55 | $14K |
| 85027 | <1% | 7,633 | $12K | |
| 54360 | <1% | 13 | $12K | |
| 81025 | <1% | 5,320 | $12K | |
| 73564 | <1% | 580 | $11K | |
| 74174 | <1% | 82 | $11K | |
| 82805 | <1% | 1,254 | $11K | |
| 81003 | <1% | 13,171 | $11K | |
| 54300 | <1% | 14 | $10K | |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 1,616 | $10K |
| A9555 | Rubidium rb-82, diagnostic, per study dose, up to 60 millicuries | <1% | 80 | $10K |
| 99152 | <1% | 1,501 | $10K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 5,269 | $9K |
| 12011 | <1% | 241 | $9K | |
| 93017 | <1% | 870 | $9K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 6,760 | $9K |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | <1% | 1,784 | $9K |
| 86703 | <1% | 1,462 | $9K | |
| 72100 | <1% | 681 | $9K | |
| 73590 | <1% | 686 | $9K | |
| J1815 | Injection, insulin, per 5 units | <1% | 4,947 | $8K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 573 | $8K |
| 80061 | Lipid panel | <1% | 2,947 | $8K |
| 99201 | <1% | 684 | $8K | |
| 87077 | <1% | 2,998 | $8K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 1,305 | $7K |
| 73110 | <1% | 419 | $7K | |
| 97162 | <1% | 921 | $7K | |
| 86901 | <1% | 7,547 | $6K | |
| 73090 | <1% | 425 | $6K | |
| 82962 | <1% | 10,813 | $6K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 18,688 | $6K |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 8,018 | $6K |
| 84100 | <1% | 4,973 | $6K | |
| 73562 | <1% | 352 | $6K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 3,202 | $5K |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 3,656 | $5K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 332 | $5K |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 4,304 | $5K |
| 86140 | <1% | 2,876 | $5K | |
| 87081 | <1% | 1,522 | $5K | |
| 74019 | <1% | 311 | $5K | |
| 99153 | Mod sedat endo service >5yrs | <1% | 1,159 | $4K |
| 72170 | <1% | 468 | $4K | |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 2,110 | $4K |
| 12001 | <1% | 130 | $4K | |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 5,752 | $4K |
| 80320 | <1% | 2,829 | $4K | |
| 86850 | <1% | 4,791 | $4K | |
| 84439 | <1% | 1,363 | $4K | |
| 14040 | <1% | 24 | $4K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 1,703 | $3K |
| 94644 | <1% | 175 | $3K | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 767 | $3K |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 5,643 | $3K |
| A9579 | Injection, gadolinium-based magnetic resonance contrast agent, not otherwise specified (nos), per ml | <1% | 182 | $3K |
| 76770 | <1% | 68 | $3K | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 4,840 | $3K |
| 86900 | <1% | 4,961 | $3K | |
| 87070 | <1% | 854 | $3K | |
| 71250 | <1% | 53 | $3K | |
| 85007 | <1% | 3,100 | $3K | |
| 86592 | <1% | 1,481 | $3K | |
| 97166 | <1% | 415 | $3K | |
| 73502 | <1% | 218 | $3K | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 734 | $3K |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 627 | $3K |
| 74022 | <1% | 170 | $3K | |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 25 | $3K |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 1,337 | $3K |
| J1790 | Injection, droperidol, up to 5 mg | <1% | 462 | $2K |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 43 | $2K |
| J0360 | Injection, hydralazine hcl, up to 20 mg | <1% | 1,155 | $2K |
| 84145 | <1% | 413 | $2K | |
| J0561 | Injection, penicillin g benzathine, 100,000 units | <1% | 12 | $2K |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 2,892 | $2K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 66 | $2K |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 3,604 | $2K |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 1,570 | $2K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 482 | $2K |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 883 | $2K |
| C9113 | Injection, pantoprazole sodium, per vial | <1% | 3,128 | $2K |
| 82010 | <1% | 516 | $2K | |
| A9502 | Technetium tc-99m tetrofosmin, diagnostic, per study dose | <1% | 55 | $2K |
| J2704 | Injection, propofol, 10 mg | <1% | 6,081 | $2K |
| J3360 | Injection, diazepam, up to 5 mg | <1% | 121 | $2K |
| J3486 | Injection, ziprasidone mesylate, 10 mg | <1% | 74 | $2K |
| 85652 | <1% | 1,571 | $1K | |
| C1769 | Guide wire | <1% | 575 | $1K |
| 73080 | <1% | 85 | $1K | |
| 84112 | <1% | 98 | $1K | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 7,157 | $1K |
| 29125 | <1% | 42 | $1K | |
| J7510 | Prednisolone oral, per 5 mg | <1% | 91 | $1K |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 837 | $1K |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 800 | $1K |
| 76775 | <1% | 48 | $1K | |
| J3480 | Injection, potassium chloride, per 2 meq | <1% | 1,336 | $986.38 |
| 87210 | <1% | 595 | $977.75 | |
| 10060 | <1% | 12 | $945.05 | |
| 82728 | <1% | 236 | $860.92 | |
| 36430 | <1% | 64 | $848.28 | |
| P9016 | Red blood cells, leukocytes reduced, each unit | <1% | 28 | $834.90 |
| C9399 | Unclassified drugs or biologicals | <1% | 195 | $767.62 |
| 87205 | <1% | 1,027 | $760.92 | |
| 80069 | <1% | 739 | $738.94 | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 4,529 | $729.44 |
| 87631 | <1% | 658 | $711.00 | |
| 87807 | <1% | 119 | $699.10 | |
| 12002 | <1% | 16 | $673.68 | |
| 71101 | <1% | 43 | $672.56 | |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 531 | $626.22 |
| J8540 | Dexamethasone, oral, 0.25 mg | <1% | 293 | $563.68 |
| 82140 | <1% | 161 | $562.78 | |
| 97116 | <1% | 231 | $516.23 | |
| 82553 | <1% | 200 | $510.96 | |
| 80329 | <1% | 821 | $488.62 | |
| J1940 | Injection, furosemide, up to 20 mg | <1% | 354 | $442.42 |
| 84550 | <1% | 240 | $436.94 | |
| 73552 | <1% | 27 | $406.31 | |
| 64488 | <1% | 243 | $383.76 | |
| 87147 | <1% | 55 | $331.17 | |
| 88307 | <1% | 103 | $323.16 | |
| 80076 | <1% | 168 | $296.77 | |
| 86923 | <1% | 97 | $289.46 | |
| 73070 | <1% | 17 | $284.74 | |
| 73140 | <1% | 17 | $283.60 | |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 48 | $281.90 |
| 82731 | <1% | 13 | $278.85 | |
| 83615 | <1% | 139 | $269.80 | |
| 72040 | <1% | 14 | $261.00 | |
| A9270 | Non-covered item or service | <1% | 12,240 | $257.12 |
| 80047 | <1% | 102 | $200.78 | |
| 90658 | <1% | 81 | $193.80 | |
| 72072 | <1% | 24 | $178.19 | |
| G0235 | Pet imaging, any site, not otherwise specified | <1% | 35 | $173.25 |
| J1171 | Injection, hydromorphone, 0.1 mg | <1% | 97 | $151.25 |
| 94726 | <1% | 15 | $146.60 | |
| 88304 | <1% | 161 | $128.20 | |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 113 | $126.91 |
| 86735 | <1% | 25 | $106.80 | |
| 82746 | <1% | 44 | $95.86 | |
| J3411 | Injection, thiamine hcl, 100 mg | <1% | 36 | $85.75 |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | <1% | 19 | $83.00 |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | <1% | 181 | $79.80 |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 45 | $78.44 |
| 82607 | <1% | 47 | $71.96 | |
| 83540 | <1% | 78 | $69.13 | |
| 84132 | <1% | 89 | $65.99 | |
| 97597 | <1% | 198 | $64.23 | |
| 85014 | <1% | 160 | $62.20 | |
| 83550 | <1% | 55 | $55.44 | |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | <1% | 182 | $46.69 |
| 86308 | <1% | 15 | $42.36 | |
| 90686 | <1% | 25 | $38.52 | |
| 85045 | <1% | 31 | $32.79 | |
| 85018 | <1% | 77 | $27.54 | |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 546 | $25.11 |
| J2175 | Injection, meperidine hydrochloride, per 100 mg | <1% | 64 | $15.24 |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 199 | $12.23 |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 33 | $11.13 |
| 87340 | <1% | 26 | $8.46 | |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | 0% | 734 | $0.00 |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 491 | $0.00 |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | 0% | 100 | $0.00 |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 494 | $0.00 |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | 0% | 159 | $0.00 |
| 00920 | 0% | 214 | $0.00 | |
| G8989 | Self care functional limitation, discharge status, at discharge from therapy or to end reporting | 0% | 55 | $0.00 |
| 88312 | 0% | 29 | $0.00 | |
| 00840 | 0% | 58 | $0.00 | |
| S2900 | Surgical techniques requiring use of robotic surgical system (list separately in addition to code for primary procedure) | 0% | 267 | $0.00 |
| G8980 | Mobility: walking & moving around functional limitation, discharge status, at discharge from therapy or to end reporting | 0% | 112 | $0.00 |
| G8988 | Self care functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 279 | $0.00 |
| 0250 | 0% | 34 | $0.00 | |
| G8987 | Self care functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 278 | $0.00 |
| P9612 | Catheterization for collection of specimen, single patient, all places of service | 0% | 18 | $0.00 |
| 97535 | Self-care/home management training, each 15 minutes | 0% | 19 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialMORISSETTE, DANIEL (CHIEF FINANCIAL OFFICER)
Parent organizationDIGNITY HEALTH
| Provider | Location | Paid |
|---|---|---|
| Dignity Health | San Bernardino, CA | $133.09M |
| Dignity Health | Phoenix, AZ | $126.19M |
| Dignity Health | Bakersfield, CA | $109.22M |
| Dignity Health | Merced, CA | $106.54M |
| Dignity Health | Carmichael, CA | $97.28M |
| Dignity Health | Oxnard, CA | $96.24M |
| Dignity Health | Redding, CA | $92.21M |
| Dignity Health | Long Beach, CA | $59.98M |
| Dignity Health | Sacramento, CA | $45.52M |
| Dignity Health | Folsom, CA | $45.14M |
| Dignity Health | Red Bluff, CA | $39.92M |
| Dignity Health | Santa Cruz, CA | $33.59M |
| Dignity Health | Gilbert, AZ | $28.49M |
| Dignity Health | Glendale, AZ | $26.30M |
| Dignity Health | Mount Shasta, CA | $15.62M |
| Dignity Health | Henderson, NV | $8.52M |
| Dignity Health | Las Vegas, NV | $7.93M |
| Dignity Health | Camarillo, CA | $6.31M |
| Dignity Health | Santa Maria, CA | $5.79M |
| Dignity Health | Corning, CA | $3.24M |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.